Abstract: The prevalence of hidradenitis suppurativa (HS) in general population ranges from 1% to 4%, while its etiopathogenesis is still incompletely determined and multifactorial. The management of these diseases is complex, as the current therapy does not a curative role but rather aims at reducing the chronic inflammation and maintaining the remission state, by preventing the worsening and progression of the disease